Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Both hormones bind to specific receptors on ovarian cells. Follicle‑stimulating hormone promotes growth and maturation of ovarian follicles and estrogen production, while luteinising hormone triggers ovulation and supports luteal phase development. Together they coordinate the hormonal cascade required for normal menstrual cycles and fertility.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount, frequency and duration of treatment based on the patient’s clinical condition, ovarian response and treatment goals. No standard dosing regimen is provided in public information.

Meriofert Set is intended for use before conception to achieve pregnancy. Its safety in established pregnancy or while breastfeeding has not been established, and it is generally discontinued once pregnancy is confirmed. Consultation with a healthcare professional is essential for any concerns.

To order, submit an enquiry on the Meriofert Set product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Meriofert Set contains both recombinant FSH and LH, whereas some alternatives provide only FSH (e.g., recombinant FSH alone) or are derived from urinary sources. The combined formulation can more closely mimic natural pituitary output, potentially improving follicular development in certain protocols, but choice depends on clinical protocol, cost and physician preference.

Meriofert Set must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain using validated insulated containers.

The solution is reconstituted according to the manufacturer’s instructions and administered by a trained healthcare professional via intramuscular or subcutaneous injection. The injection site is typically the abdomen or thigh, and the exact technique follows local clinical guidelines.

The most serious adverse events include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, thromboembolic complications such as deep‑vein thrombosis, and rare but life‑threatening allergic reactions like anaphylaxis. Prompt medical attention is required if any of these occur.

Meriofert Set is contraindicated in women with active ovarian cysts, estrogen‑dependent tumors, uncontrolled thyroid disease, severe ovarian hyperstimulation syndrome, or known hypersensitivity to any component of the product. It should also be avoided in patients for whom pregnancy is not desired during treatment.